Results: 4

1.
Figure 4

Figure 4. From: Prognostic Value of Ishak Fibrosis Stage: Findings from the HALT-C Trial.

Cumulative incidence of transplantation or liver related death according to baseline Ishak fibrosis stage. a) all (non-fragmented and fragmented) biopsies, b) non-fragmented

James E. Everhart, et al. Hepatology. 2010 February;51(2):10.1002/hep.23315.
2.
Figure 1

Figure 1. From: Prognostic Value of Ishak Fibrosis Stage: Findings from the HALT-C Trial.

Examples of fragmented biopsies. Specimen on left, which only has fibrosis focally along the edge of one fragment, was interpreted as Ishak stage 3. Specimen on right has fibrosis enveloping several fragments and was interpreted as Ishak stage 6.

James E. Everhart, et al. Hepatology. 2010 February;51(2):10.1002/hep.23315.
3.
Figure 2

Figure 2. From: Prognostic Value of Ishak Fibrosis Stage: Findings from the HALT-C Trial.

Cumulative, 6-year incidence of first clinical liver disease outcome according to baseline Ishak fibrosis stage. a) all (non-fragmented and fragmented) biopsies, b) non-fragmented biopsies and c) fragmented biopsies.

James E. Everhart, et al. Hepatology. 2010 February;51(2):10.1002/hep.23315.
4.
Figure 3

Figure 3. From: Prognostic Value of Ishak Fibrosis Stage: Findings from the HALT-C Trial.

Hazard rate ratios and 95% confidence intervals for clinical outcomes over 6 years for Ishak fibrosis stage relative to the next lower stage.

James E. Everhart, et al. Hepatology. 2010 February;51(2):10.1002/hep.23315.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk